Donepezil and memantine combination therapy—taking both Alzheimer's medicines together—can cause diarrhea, nausea, vomiting, appetite loss, dizziness, headache, and easy bruising. Caregivers should promptly report fainting, possible gastrointestinal bleeding, seizures, or trouble urinating. The fixed-dose capsule Namzaric is not labeled for every type or stage of dementia. According to the March 6, 2026 DailyMed label, it is intended for moderate-to-severe Alzheimer's dementia in people already stabilized on donepezil 10 mg daily.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which side effects are most common?
- When should caregivers monitor most closely?
- Which warning signs need prompt attention?
- What health conditions and medicines should the prescriber know about?
- How certain is the evidence about rare serious events?
Which side effects are most common?
Memantine's common adverse effects include headache, diarrhea, and dizziness. donepezil's include diarrhea, appetite loss, vomiting, nausea, and easy bruising. In controlled trials of donepezil 10 mg for severe Alzheimer's, diarrhea affected 10% of participants, compared with 4% taking placebo.
Vomiting and appetite loss each occurred in 8% versus 4%, nausea in 6% versus 2%, and bruising in 5% versus 2%, as reported in the DailyMed prescribing information. Those percentages come from donepezil trials, not direct trials of the fixed-dose combination. They show which problems deserve attention but cannot predict one person's experience.
When should caregivers monitor most closely?
Donepezil-related nausea, vomiting, and diarrhea are often mild and temporary. However, they may continue for one to three weeks after treatment begins, making the starting period especially important.
Caregivers should also watch closely after a dose increase. A simple daily record can help distinguish an isolated symptom from a developing pattern:.
- Note the treatment start or dose-change date.
- Record symptoms, their timing, and how long they last.
- Track appetite, vomiting, diarrhea, dizziness, fainting, and unusual bruising.
- Share a clear timeline with the prescriber when reporting a concern.
Which warning signs need prompt attention?
Donepezil can slow the heart rate or interfere with the heart's electrical signaling. Heart block and fainting can occur even without a previously diagnosed conduction disorder.
The FDA-label warnings published by DailyMed advise promptly reporting fainting, particularly in someone with heart problems. Donepezil's cholinergic action can also increase stomach-acid secretion. Caregivers should monitor for ulcer or gastrointestinal-bleeding symptoms, especially when the person has a history of ulcers or takes aspirin or another nonsteroidal anti-inflammatory drug.
What health conditions and medicines should the prescriber know about?
Tell the prescriber about trouble urinating, seizures, asthma, chronic obstructive pulmonary disease, or planned anesthesia. The label warns about possible bladder obstruction, convulsions, worsening pulmonary disease, and exaggerated muscle relaxation with succinylcholine-type anesthesia.
Memantine requires another less obvious precaution: alkaline urine can reduce its clearance by about 80% at a urine pH of 8. Sodium bicarbonate, carbonic-anhydrase inhibitors, renal tubular acidosis, and severe urinary-tract infection are listed as possible contributors. Caregivers should report these medicines or conditions rather than trying to assess urine pH themselves.
How certain is the evidence about rare serious events?
Postmarketing reports have included renal failure, severe skin reactions, suicidal thoughts, heart block, seizures, and hallucinations. These reports matter because they can identify potential safety signals outside controlled trials.
They do not establish how often an event occurs or prove that the medicine caused it. As the DailyMed label explains, postmarketing reports are voluntary and come from a population of uncertain size. A caregiver should document when a sudden or severe change began and report it without assuming either that the medicine caused it or that dementia alone explains it.
